Biogen (NASDAQ:BIIB) Shares Acquired Rep. Maria Elvira Salazar

Posted by on Jun 11th, 2026

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on May 11th. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

  • Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
  • Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
  • Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
  • Purchased $1,001 – $15,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
  • Purchased $15,001 – $50,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
  • Purchased $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
  • Sold $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 5/12/2026.
  • Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/12/2026.
  • Purchased $50,001 – $100,000 in shares of Biogen (NASDAQ:BIIB) on 5/11/2026.
  • Sold $1,001 – $15,000 in shares of Whirlpool (NYSE:WHR) on 5/11/2026.

Biogen Trading Down 2.4%

BIIB opened at $194.24 on Thursday. The firm has a market cap of $28.68 billion, a price-to-earnings ratio of 20.84 and a beta of 0.20. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $205.97. The stock has a fifty day moving average price of $188.07 and a 200-day moving average price of $184.03.

Biogen (NASDAQ:BIIB – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company posted $3.02 EPS. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BIIB. Morgan Stanley upped their target price on Biogen from $200.00 to $206.00 and gave the company an “equal weight” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. upped their target price on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Biogen in a research report on Thursday, May 14th. Evercore began coverage on Biogen in a research report on Friday, May 15th. They set an “outperform” rating on the stock. Finally, Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $217.26.

Get Our Latest Stock Analysis on BIIB

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

  • Positive Sentiment: Needham upgraded Biogen to Buy and set a $255 price target, citing a stronger outlook for the commercial portfolio and multiple Phase 3 readouts through 2029, including potential upside from Leqembi and recently acquired products. Article Title
  • Positive Sentiment: At Biogen’s 2026 annual meeting, shareholders backed the board, auditor, and pay policies, which suggests governance support and no major shareholder revolt. Article Title
  • Neutral Sentiment: Commentary comparing Biogen with other biotech stocks says the company has recently outperformed peers and analysts remain reasonably upbeat, reinforcing a stable sentiment backdrop rather than a new catalyst. Article Title
  • Negative Sentiment: The Schall Law Firm announced a securities-law investigation into whether Biogen made false or misleading statements or omitted material information, adding headline risk and potential litigation overhang. Article Title
  • Negative Sentiment: Pomerantz LLP also launched an investor investigation into Biogen, reinforcing concerns that the stock could face legal scrutiny and additional uncertainty. Article Title

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Biogen by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock valued at $3,070,514,000 after purchasing an additional 157,857 shares during the period. Geode Capital Management LLC increased its holdings in shares of Biogen by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after purchasing an additional 130,618 shares during the period. Norges Bank acquired a new position in shares of Biogen in the fourth quarter valued at about $464,408,000. Invesco Ltd. boosted its stake in shares of Biogen by 4.2% in the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after buying an additional 98,001 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of Biogen by 3.3% in the fourth quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company’s stock worth $409,180,000 after buying an additional 73,478 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Biogen Company Profile

(Get Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Featured Articles

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.